The US FDA has not yet found an association between oral bisphosphonates and the risk of atypical subtrochanteric femur fractures,

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2010年 / 1293卷 / 1期
关键词：
Public Health; Clinical Trial; Osteoporosis; Bisphosphonates; Healthcare Professional;
D O I：
10.2165/00128415-201012930-00004
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2 / 2
相关论文
共 17 条
  • [11] Association between alendronate and atypical femur fractures: a meta-analysis
    Liu, Lu
    Li, Chunyan
    Yang, Peng
    Zhu, Jian
    Gan, Dongmei
    Bu, Le
    Zhang, Manna
    Sheng, Chunjun
    Li, Hong
    Qu, Shen
    ENDOCRINE CONNECTIONS, 2015, 4 (01):
  • [12] FDA Statement on Relationship Between Bisphosphonate Use and Atypical Subtrochanteric and Femoral Shaft Fractures: A Considered Opinion
    Rogers, Lee F.
    Taljanovic, Mihra
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2010, 195 (03) : 563 - 566
  • [13] Risk of atypical femoral fractures and osteonecrosis of the jaw associated with alendronate use compared with other oral bisphosphonates
    Kharazmi, Mohammad
    Hallberg, Par
    Warfvinge, Gunnar
    Michaelsson, Karl
    RHEUMATOLOGY, 2014, 53 (10) : 1911 - 1913
  • [14] The association between adherence with oral bisphosphonates and the risk of breast cancer in post-menopausal women
    Rouach, Vanessa
    Goldshtein, Inbal
    Buch, Assaf
    Catane, Raphael
    Chodick, Gabriel
    Stern, Naftali
    Shalev, Varda
    Cohen, Daniel
    JOURNAL OF BONE ONCOLOGY, 2019, 16 : 1 - 7
  • [15] The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy
    Lo, Joan C.
    Hui, Rita L.
    Grimsrud, Christopher D.
    Chandra, Malini
    Neugebauer, Romain S.
    Gonzalez, Joel R.
    Budayr, Amer
    Lau, Gene
    Ettinger, Bruce
    BONE, 2016, 85 : 142 - 147
  • [16] A study by US researchers has found that while short-term oral contraceptive use may not be associated with the risk of breast cancer
    Reactions Weekly, 2007, 1150 (1) : 5 - 5
  • [17] The US FDA has issued an Early Communication of its ongoing safety review about association between bisphosphonate use and atrial fibrillation (AF)
    Reactions Weekly, 2007, 1172 (1) : 3 - 3
12